NEW YORK (GenomeWeb) — SeraCare Life Sciences announced today that it has signed an agreement under which it will offer AccuRef Diagnostics' line of CRISPR-engineered cell line reference materials.
Under the terms of the deal, Milford, Massachusetts-based SeraCare will market and sell AccuRef's portfolio of CRISPR-engineered cell line-based cancer reference materials beginning in January in all markets except for China. The deal includes products geared for low-to-mid plex clinical genomic applications such as qPCR, digital PCR, Sanger sequencing, mass spec, and small targeted next-generation sequencing gene panels.
Additional terms were not disclosed.
AccuRef — a Milpitas, California-based division of global molecular and cellular reference standards provider Applied StemCell — was established last year.